Posted in | News | Medical Robotics

Preventice Clears FDA for Commercializing BodyGuardian Remote Monitoring System

Preventice has declared that it has received 510(k) clearance for its BodyGuardian Remote Monitoring System (RMS) from the U.S. Food and Drug Administration (FDA).

Jointly developed with Mayo Clinic, the BodyGuardian System is based on advanced algorithms that enable remote monitoring of patients with cardiac arrhythmias. Using BodyGuardian System, medical experts can track key biometrics when the patient is external to the clinical setting. By fastening a small body sensor onto the patient's chest, key data such as the patient's activity level, ECG, heart rate, and respiration rate can be collected. Using mobile phone technology, patient data can be conveyed to physicians. Remote patient monitoring strengthens the bond between patients and their medical team.

Following the achievement of FDA clearance, Preventice can commercialize BodyGuardian to clinics, hospitals and medical centers for adoption to detect and track non-lethal cardiac arrhythmias in ambulatory patients. The BodyGuardian RMS is yet to be commercially available but can be recommended by qualified physicians for specific diagnostic and post-procedure monitoring. The BodyGuardian RMS will be commercially available by 2012 end.

There is rapid implementation of wireless monitoring. A recent research study from Berg Insight states that around 2.2 M global patients have been estimated to be using this type of technology. Berg's industry analysts hope increase in the adoption of wireless monitoring to attain 4.9 M by 2016. Furthermore, Technavio anticipates global patient monitoring market to reach $9.3 B by 2014.

BodyGuardian RMS is built on the Preventice Care Platform, which is a cloud-based mHealth platform that is capable of gathering real-time data from devices and providing information to medical monitoring experts worldwide.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kaur, Kalwinder. (2019, February 20). Preventice Clears FDA for Commercializing BodyGuardian Remote Monitoring System. AZoRobotics. Retrieved on October 10, 2024 from https://www.azorobotics.com/News.aspx?newsID=3202.

  • MLA

    Kaur, Kalwinder. "Preventice Clears FDA for Commercializing BodyGuardian Remote Monitoring System". AZoRobotics. 10 October 2024. <https://www.azorobotics.com/News.aspx?newsID=3202>.

  • Chicago

    Kaur, Kalwinder. "Preventice Clears FDA for Commercializing BodyGuardian Remote Monitoring System". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=3202. (accessed October 10, 2024).

  • Harvard

    Kaur, Kalwinder. 2019. Preventice Clears FDA for Commercializing BodyGuardian Remote Monitoring System. AZoRobotics, viewed 10 October 2024, https://www.azorobotics.com/News.aspx?newsID=3202.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.